NUS · CIK 0001021561
What Nu Skin Enterprises, Inc. told the SEC could break it.
Nu Skin's disclosures center on a direct-selling model concentrated in a few markets and built on a fluctuating sales force. About 74% of its revenue comes from outside the U.S., concentrated in Mainland China, South Korea and Japan (where it also runs its own China manufacturing), and its business depends on recruiting and retaining Sales Leaders, Paid Affiliates and Customers — a base that shrank sharply in 2025, with South Korean customers down 28% and Mainland China Sales Leaders down 32%. That model is heavily regulated, with several markets capping the sales compensation it can pay (30% in China, 35% in South Korea). On supply, it depends on sole suppliers that own the formulations and IP for certain products, with one third-party supplier exceeding 10% of product purchases.
4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Geographic concentration
- revenue concentrated in four markets (Mainland China, South Korea, U.S., Japan); China manufacturing concentration; ~74% international revenue with FX exposurehigh
Nu Skin's revenue is concentrated in four major markets — Mainland China, South Korea, the United States and Japan — with ~74% of revenue generated internationally (only ~26% from the U.S.), and in Mainland China it operates its own manufacturing facilities producing the majority of products sold there; this geographic concentration exposes it to China/Korea/Japan demand swings (South Korea customers fell 28% and China Sales Leaders fell 32% in 2025) and to foreign-currency fluctuations.
“In 2025, we generated approximately 26% of our revenue from the United States (consisting of our Nu Skin United States and Rhyz businesses) and the remainder from our international markets.”
Other disclosures
- revenue depends on recruiting/retaining a fluctuating direct-sales force (Sales Leaders, Paid Affiliates, Customers) — sharp 2025 declineshigh
Nu Skin's revenue depends on its ability to recruit, retain and drive productivity in its direct-sales force — Sales Leaders, Paid Affiliates and Customers — which fluctuates materially: from December 2024 to December 2025, Customers in South Korea declined 28% and Sales Leaders in Mainland China declined 32%; continued attrition or failure to drive sales-force growth/productivity could further harm operating results.
“For example, from December 31, 2024 to December 31, 2025, our Customers in South Korea declined 28% and our Sales Leaders in Mainland China declined 32%.”
SEC filing →As of 2026
Sole-source dependency
- sole suppliers that own/control product formulations and IP; one third-party supplier >10% of product purchases; licensed-in productshigh
Nu Skin obtains products, ingredients and packaging from third-party suppliers and manufacturers, including sole suppliers that own or control the formulations, ingredients or IP for certain products, and it licenses the right to distribute some products from third parties; in 2025 one third-party supplier (plus two owned manufacturing subsidiaries) each accounted for more than 10% of product purchases, so loss of a sole supplier or failure to renew a key contract could disrupt supply.
“We obtain some products and ingredients from sole suppliers that own or control the product formulations, ingredients or other intellectual property rights associated with such products. We also license the right to distribute some of our products from third parties.”
SEC filing →As of 2026
Regulatory & policy
- direct-selling regulation (China 30% / South Korea 35% sales-compensation caps) plus FDA/FTC/CPSC and China SAMR product regulationmedium
Nu Skin's direct-selling model and products are heavily regulated worldwide — several markets (Mainland China, South Korea, Indonesia, Vietnam) cap the sales compensation it can pay its sales force (e.g. 30% in China, 35% in South Korea), and its products are regulated by the FDA, FTC, CPSC and equivalents abroad (China SAMR, Korea MFDS, Japan MHLW); regulatory investigations or sanctions (it notes prior adverse-publicity events) could bring fines, license revocation or material business harm.
“Several markets, including Mainland China, South Korea, Indonesia and Vietnam, impose limits on the amount of sales compensation we can pay to our sales force.”
SEC filing →As of 2026
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch